Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Globe Life Q3 net income falls 7% year over year to $361.11 million; Q3 total premium revenue rises 7% year over year to $1.31 billion

Globe Life Q3 net income falls 7% year over year to $361.11 million; Q3 total premium revenue rises 7% year over year to $1.31 billion

BitgetBitget2026/10/21 20:19
  • Globe Life’s third-quarter 2026 net income fell 7% year over year to $361.11 million.
  • Total premium revenue rose 7% to $1.31 billion, while health insurance revenue climbed 16% to $446.86 million year over year.
  • Full-year 2026 share repurchase spending is expected to reach $725 million–$775 million, above previous guidance of $670 million–$700 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Globe Life Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA77545) on October 21, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"Demand destruction" and tug-of-war over Saudi attack risks, international oil prices fall more than 2%

Traders weighed the impact of Saudi attack risks and sharply reduced demand, causing oil prices to fall more than 2%.

智通财经•2026/10/26 06:41
"Demand destruction" and tug-of-war over Saudi attack risks, international oil prices fall more than 2%

JPMorgan maintains "Neutral" rating on Johnson & Johnson (JNJ.US): Strong data from two anti-cancer drugs, but valuation premium limits upside potential

Johnson & Johnson’s new prostate cancer drug and head and neck cancer drug Ervantumab both released positive data at ESMO. JPMorgan stated that the pipeline shows differentiated potential but valuations are relatively high, maintaining a Neutral rating.

智通财经•2026/10/26 06:37